Trial Search Results
Study in Subjects With Small Primary Choroidal Melanoma
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Stanford is currently not accepting patients for this trial.
- Drug: Light-activated AU-011
Phase 1/Phase 2
- Diagnosis of choroidal melanoma
- Have known contraindications or sensitivities to the study drug
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study